360 ONE Asset announced an investment in OneSource Specialty Pharma, a pharma CDMO in India. 360 ONE Asset is acquiring a stake from an existing investor. OneSource is a player in biologics, drug-device combinations, complex injectables, and soft gelatin capsules.
OneSource has the expertise to develop and manufacture complex products such as GLP-1 drugs and novel biologics. It has five automated manufacturing plants, including four US-FDA-approved sites with impeccable compliance records, and a team of over 1,200 employees, including 100+ scientists and techno-commercial experts.
OneSource aims to capitalise on the burgeoning demand for these specialised solutions and has built strong relationships with globally reputed pharma and biotech firms.
The post appeared first on .